We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Accenture, Veeva Inks Deal, Boosts Life Sciences Industry
Read MoreHide Full Article
Accenture PLC (ACN - Free Report) and global life sciences company, Veeva Systems Inc. (VEEV - Free Report) recently announced a strategic partnership to provide Veeva Vault RIM solutions to life sciences and pharma companies.
The collaboration aims in accelerating the life sciences industry’s move to more customer-centric engagement by bringing latest medicines to patients sooner.
Vault RIM is a cloud-based platform that unites submissions documents, product registration and helps store the interaction into a single source for all regulatory information. It provides an intuitive, customer-friendly experience for quick and easy access to data. The collaboration reflects growing demand for Veeva’s solutions among major life sciences and pharmaceutical companies.
The life sciences industry has been quite slow in adopting cloud-based software as compared with other industries. However, we believe that the industry is gradually realizing the benefits of cloud-based applications particularly due to the rising regulations and budgetary constraints. The cost-effectiveness of cloud-based applications over in-premise applications is attracting life science companies. Moreover, uncertain regulatory environment has increased demand from software vendors who are well-acquainted with the industry trends.
We believe that the collaboration will aid Accenture to bring Veeva’s industry expertise and innovative product portfolio to fulfill these growing demands of the life sciences industry.
We also believe that growing traction of Veeva Vault RIM in the life sciences industry will provide significant growth opportunities for Accenture.
Meanwhile, strategic deals with companies like Accenture will strengthen Veeva’s customer base which in turnwilldrive subscription revenues.
To Conclude
Accenture stock has gained 14.6% year to date, outperforming the 14.5% rally of the industry it belongs to.
The company’s long-term prospects look promising, driven by sustained focus on innovative product roll outs, consistent investments in enhancing digital and marketing capabilities, along with major acquisitions. Additionally, we believe regular acquisitions will significantly contribute to the revenue stream.
Currently, Accenture caries a Zacks Rank #2 (Buy).
Long-term expected EPS growth rates for Applied Materials and NVIDIA are 17.1% and 10.3%, respectively.
Can Hackers Put Money INTO Your Portfolio?
Earlier this month, credit bureau Equifax announced a massive data breach affecting 2 out of every 3 Americans. The cybersecurity industry is expanding quickly in response to this and similar events. But some stocks are better investments than others.
Zacks has just released Cybersecurity! An Investor’s Guide to help Zacks.com readers make the most of the $170 billion per year investment opportunity created by hackers and other threats. It reveals 4 stocks worth looking into right away.
Image: Bigstock
Accenture, Veeva Inks Deal, Boosts Life Sciences Industry
Accenture PLC (ACN - Free Report) and global life sciences company, Veeva Systems Inc. (VEEV - Free Report) recently announced a strategic partnership to provide Veeva Vault RIM solutions to life sciences and pharma companies.
The collaboration aims in accelerating the life sciences industry’s move to more customer-centric engagement by bringing latest medicines to patients sooner.
Vault RIM is a cloud-based platform that unites submissions documents, product registration and helps store the interaction into a single source for all regulatory information. It provides an intuitive, customer-friendly experience for quick and easy access to data. The collaboration reflects growing demand for Veeva’s solutions among major life sciences and pharmaceutical companies.
The life sciences industry has been quite slow in adopting cloud-based software as compared with other industries. However, we believe that the industry is gradually realizing the benefits of cloud-based applications particularly due to the rising regulations and budgetary constraints. The cost-effectiveness of cloud-based applications over in-premise applications is attracting life science companies. Moreover, uncertain regulatory environment has increased demand from software vendors who are well-acquainted with the industry trends.
We believe that the collaboration will aid Accenture to bring Veeva’s industry expertise and innovative product portfolio to fulfill these growing demands of the life sciences industry.
We also believe that growing traction of Veeva Vault RIM in the life sciences industry will provide significant growth opportunities for Accenture.
Meanwhile, strategic deals with companies like Accenture will strengthen Veeva’s customer base which in turnwilldrive subscription revenues.
To Conclude
Accenture stock has gained 14.6% year to date, outperforming the 14.5% rally of the industry it belongs to.
The company’s long-term prospects look promising, driven by sustained focus on innovative product roll outs, consistent investments in enhancing digital and marketing capabilities, along with major acquisitions. Additionally, we believe regular acquisitions will significantly contribute to the revenue stream.
Currently, Accenture caries a Zacks Rank #2 (Buy).
Other top-ranked stocks in the broader technology space are Applied Materials, Inc. (AMAT - Free Report) and NVIDIA Corporation (NVDA - Free Report) , both sporting a Zacks Rank #1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
Long-term expected EPS growth rates for Applied Materials and NVIDIA are 17.1% and 10.3%, respectively.
Can Hackers Put Money INTO Your Portfolio?
Earlier this month, credit bureau Equifax announced a massive data breach affecting 2 out of every 3 Americans. The cybersecurity industry is expanding quickly in response to this and similar events. But some stocks are better investments than others.
Zacks has just released Cybersecurity! An Investor’s Guide to help Zacks.com readers make the most of the $170 billion per year investment opportunity created by hackers and other threats. It reveals 4 stocks worth looking into right away.
Download the new report now>>